ARKEMA LAUNCHES ETHYL ACRYLATE BASED ENTIRELY ON BIOETHANOL
*IPCC 2021 GWP100 (incl. biogenic uptake)
"This exclusive production of bio sourced Ethyl Acrylate in
"It will enable Arkema to expand its bio-based and lower-carbon specialty acrylic resins and additives for coating applications in fast growing markets, such as new energies, e-mobility, living comfort and building efficiency" said Karine ELIE, Arkema Rheology and Specialty Additives Managing Director.
This new milestone supports Arkema's roadmap to decarbonize its acrylic offerings, complementing the investment announced in 2023 to optimize production processes and reduce Carling's scopes 1 and 2 emissions by 20%.
For more information, visit www.arkema.com.
Building on its unique set of expertise in materials science, Arkema offers a portfolio of first-class technologies to address ever-growing demand for new and sustainable materials. With the ambition to become in 2024 a pure player in Specialty Materials, the Group is structured into 3 complementary, resilient and highly innovative segments dedicated to Specialty Materials - Adhesive Solutions, Advanced Materials, and Coating Solutions - accounting for some 92% of Group sales in 2023, and a well-positioned and competitive Intermediates segment. Arkema offers cutting-edge technological solutions to meet the challenges of, among other things, new energies, access to water, recycling, urbanization and mobility, and fosters a permanent dialogue with all its stakeholders. The Group reported sales of around € 9.5 billion in 2023, and operates in some 55 countries with 21,100 employees worldwide.
Press contact: Mike Crisp | +1 864 525 9307 |
View original content to download multimedia:https://www.prnewswire.com/news-releases/arkema-launches-ethyl-acrylate-based-entirely-on-bioethanol-302273586.html
SOURCE Arkema
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Invitation to Minesto's webinar: Q2 update by CEO
- FairJourney Bio Delivers Antibody Engineering for Novel Tumor-Conditional IL-12 Therapeutic Approach That Unlocks the Potential of Localized Cytokine Activation
- Futu Announces Second Quarter 2026 Unaudited Financial Results
Create E-mail Alert Related Categories
PRNewswire, Press ReleasesRelated Entities
ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share